Catheter Precision (NYSEAMERICAN:VTAK) Posts Quarterly Earnings Results, Beats Estimates By $19.51 EPS

Catheter Precision (NYSEAMERICAN:VTAK) posted its quarterly earnings data on Monday. The company reported ($1.39) EPS for the quarter, topping the consensus estimate of ($20.90) by $19.51, FiscalAI reports. Catheter Precision had a negative return on equity of 84.13% and a negative net margin of 1,297.56%.The firm had revenue of $0.43 million for the quarter, compared to the consensus estimate of $1.60 million.

Catheter Precision Stock Down 0.8%

NYSEAMERICAN VTAK opened at $0.82 on Wednesday. The stock’s 50-day moving average price is $1.05 and its 200-day moving average price is $1.66. The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.46. Catheter Precision has a 52 week low of $0.76 and a 52 week high of $15.68. The company has a market capitalization of $2.21 million, a P/E ratio of -0.06 and a beta of -1.04.

Institutional Trading of Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC acquired a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision at the end of the most recent reporting period. Hedge funds and other institutional investors own 20.34% of the company’s stock.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.